EHDN Newsletter – 45th edition

The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]

Read More…

Novartis Global study endorsed* by EHDN

Study aims and goal: A Randomized, double-blind, placebo-controlled dose range finding study with Open-Label Extension to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LMI070/branaplam in participants with early manifest HD. No. of study sites: This Phase IIb study aims to recruit stage 1 and 2 participants at sites in Belgium, Canada, France, Germany, Hungary, […]

Read More…